0001481646false00014816462023-06-292023-06-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2023

Accolade, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39348

01-0969591

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

1201 Third Avenue, Suite 1700
Seattle, WA 98101

(Address of Principal Executive Offices and Zip Code)

(206) 926-8100

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

ACCD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02.           Results of Operations and Financial Condition.

On June 29, 2023, Accolade, Inc. (the “Company”) issued a press release reporting its financial results for the fiscal first quarter ended May 31, 2023. A copy of such press release is furnished hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, or into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as expressly set forth by reference in such a filing.

Item 9.01           Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number

Exhibit Description

99.1

Press Release titled “Accolade Announces Results for Fiscal First Quarter 2024,” dated June 29, 2023 furnished herewith

104

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Accolade, Inc.

 

Dated: June 29, 2023

 

By:

/s/ Stephen Barnes

Stephen Barnes

Chief Financial Officer

Exhibit 99.1

Graphic

Accolade Announces Results for Fiscal First Quarter 2024

Accolade exceeds guidance for fiscal first quarter and raises guidance for fiscal year 2024

SEATTLE, June 29, 2023 -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2023.

“Our consistently strong financial results reinforce our belief that an advocacy-led care delivery strategy is the key to transforming the U.S. healthcare system. We are seeing the proof points in our growing customer base and sales momentum, and also through our customers' outcomes, engagement and measurable ROI. We are especially excited by the growth we are witnessing in virtual primary care, which is the key to people living their healthiest lives. For too long, healthcare has been a series of siloed episodes. An advocacy-led care delivery strategy facilitates a coordinated patient journey and tighter collaboration across the healthcare ecosystem, while delivering better health outcomes and tremendous customer satisfaction,” said Rajeev Singh, Accolade Chief Executive Officer.

Financial Highlights for Fiscal First Quarter ended May 31, 2023

Three Months Ended May 31,

%

 

    

2023

    

2022

    

Change(3)

 

(in millions, except percentages)

 

GAAP Financial Data:

Revenue

$

93.2

$

85.5

9

%

Net loss(1)

$

(38.4)

$

(342.8)

89

%

Non-GAAP Financial Data(2):

Adjusted EBITDA

$

(12.6)

$

(15.4)

18

%

Adjusted Gross Profit

$

40.6

$

39.0

4

%

Adjusted Gross Margin

43.5

%

45.6

%

(1) A non-cash goodwill impairment charge of $299.7 million was recorded during the three months ended May 31, 2022.

(2) A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying Financial Tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

(3) Percentages are calculated from accompanying Financial Tables and may differ from percentage change of numbers in Financial Highlights table due to rounding.

Steve Barnes, Accolade Chief Financial Officer, commented, “Accolade exceeded both our top and bottom line guidance in the first fiscal quarter. Our One Accolade initiative is creating a more streamlined organization, benefiting overall costs, decision making and strategic planning. We are raising our guidance for both revenue and Adjusted EBITDA for the fiscal year and remain confident in our path to achieving profitability.”

Financial Outlook

Accolade provides forward-looking guidance on revenue and Adjusted EBITDA, a non-GAAP financial measure.

For the fiscal second quarter ending August 31, 2023, we expect:

Revenue between $93 million and $95 million

Adjusted EBITDA between $(11) million and $(14) million

For the fiscal year ending February 29, 2024, we expect:

Revenue between $410 million and $414 million
Adjusted EBITDA between $(6) million and $(12) million

Accolade has not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and has not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within the company’s control or cannot be reasonably predicted.

Quarterly Conference Call Details 

The company will host a conference call today, June 29, 2023 at 4:30 p.m. E.T. to discuss its financial results.  

 

To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI923dbf9312d54b2da4cc7883c77e68c9). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. 

  

To Listen via Internet: The conference call can be accessed via a live audio webcast that will be available online at http://ir.accolade.com

  

Replay: A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at http://ir.accolade.com.

 

Forward-Looking Statements 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “maintain,” “might,” “likely,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risks described under the heading “Risk Factors” in Accolade’s most recently filed Annual Report on Form 10-K and subsequent filings, which should be read in conjunction with any forward-looking statements. All forward-looking statements in this press release are based on information available to Accolade as of the date hereof, and it does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

About Accolade, Inc. 

Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care.


Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedInTwitter, Instagram and Facebook.

Investor Contact:

Todd Friedman, Investor Relations, IR@accolade.com

Media Contact:

Public Relations, Media@accolade.com

Source: Accolade


Financial Tables

Accolade, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (unaudited)

(In thousands, except share and per share data)

May 31, 

February 28, 

    

2023

    

2023

Assets

Current assets:

Cash and cash equivalents

$

302,870

$

321,083

Accounts receivable, net

 

22,539

23,435

Unbilled revenue

 

3,760

3,260

Current portion of deferred contract acquisition costs

 

3,933

4,022

Prepaid and other current assets

 

15,372

14,149

Total current assets

 

348,474

365,949

Property and equipment, net

 

16,608

14,763

Operating lease right-of-use assets

28,080

29,525

Goodwill

 

278,191

278,191

Intangible assets, net

 

192,829

203,202

Deferred contract acquisition costs

 

9,679

9,815

Other assets

 

1,846

1,624

Total assets

$

875,707

$

903,069

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$

5,461

$

10,155

Accrued expenses and other current liabilities

 

13,782

11,744

Accrued compensation

 

27,628

39,346

Due to customers

 

14,761

15,694

Current portion of deferred revenue

 

44,189

35,191

Current portion of operating lease liabilities

6,915

7,284

Total current liabilities

 

112,736

119,414

Loans payable, net of unamortized issuance costs

 

282,742

282,323

Operating lease liabilities

25,741

27,189

Other noncurrent liabilities

 

168

203

Deferred revenue

 

142

154

Total liabilities

 

421,529

429,283

Commitments and Contingencies

Stockholders’ equity

Common stock par value $0.0001; 500,000,000 shares authorized; 75,264,400 and 73,089,075 shares issued and outstanding at May 31, 2023 and February 28, 2023, respectively

 

8

7

Additional paid-in capital

 

1,446,873

1,428,073

Accumulated deficit

 

(992,703)

(954,294)

Total stockholders’ equity

 

454,178

473,786

Total liabilities and stockholders’ equity

$

875,707

$

903,069


Accolade, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations (unaudited)

(In thousands, except share and per share data)

Three months ended May 31, 

    

2023

    

2022

Revenue

$

93,226

$

85,528

Cost of revenue, excluding depreciation and amortization

 

54,203

 

47,615

Operating expenses:

Product and technology

 

25,899

 

26,817

Sales and marketing

 

25,033

 

25,614

General and administrative

 

16,080

 

20,238

Depreciation and amortization

 

11,640

 

11,576

Goodwill impairment

299,705

Total operating expenses

 

78,652

 

383,950

Loss from operations

 

(39,629)

 

(346,037)

Interest income (expense), net

 

921

 

(634)

Other income (expense)

 

390

 

(50)

Loss before income taxes

 

(38,318)

 

(346,721)

Income tax benefit (expense)

 

(91)

 

3,899

Net loss

$

(38,409)

$

(342,822)

Net loss per share, basic and diluted

$

(0.52)

$

(4.92)

Weighted-average common shares outstanding, basic and diluted

73,179,994

69,738,638

The following table summarizes the amount of stock-based compensation included in the condensed consolidated statements of operations:

Three months ended May 31, 

    

2023

    

2022

Cost of revenue, excluding depreciation and amortization

$

911

$

1,128

Product and technology

 

6,966

 

7,490

Sales and marketing

 

3,826

 

3,989

General and administrative

 

2,575

 

6,782

Total stock-based compensation

$

14,278

$

19,389


Accolade, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited)

(In thousands)

Three months ended May 31, 

    

2023

    

2022

Cash flows from operating activities:

Net loss

$

(38,409)

$

(342,822)

Adjustments to reconcile net loss to net cash used in

Operating activities:

Goodwill impairment

299,705

Depreciation and amortization expense

 

11,640

11,576

Amortization of deferred contract acquisition costs

 

1,116

817

Deferred income taxes

(3,999)

Noncash interest expense

 

440

419

Stock-based compensation expense

 

14,278

19,389

Changes in operating assets and liabilities, net of effect of acquisitions:

Accounts receivable and unbilled revenue

 

396

2,323

Accounts payable and accrued expenses

 

(1,690)

(1,258)

Deferred contract acquisition costs

 

(891)

(924)

Deferred revenue and due to customers

 

8,052

862

Accrued compensation

 

(11,718)

(15,598)

Other liabilities

 

(1,131)

(240)

Other assets

 

(1,370)

(711)

Net cash used in operating activities

 

(19,287)

(30,461)

Cash flows from investing activities:

Capitalized software development costs

 

(2,500)

(766)

Purchases of property and equipment

 

(877)

(506)

Net cash used in investing activities

 

(3,377)

(1,272)

Cash flows from financing activities:

Proceeds from stock option exercises

 

2,459

358

Proceeds from employee stock purchase plan

1,992

1,150

Net cash provided by financing activities

 

4,451

1,508

Net decrease in cash and cash equivalents

 

(18,213)

(30,225)

Cash and cash equivalents, beginning of period

 

321,083

365,853

Cash and cash equivalents, end of period

$

302,870

$

335,628

Supplemental cash flow information:

Interest paid

$

769

$

769

Fixed assets included in accounts payable

$

506

$

228

Other receivable related to stock option exercises

$

84

$

5

Income taxes paid

$

53

$

22


Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we use the following non-GAAP financial measures to help us evaluate trends, establish budgets, measure the effectiveness and efficiency of our operations, and determine employee incentives. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. In evaluating these non-GAAP financial measures, you should be aware that in the future we expect to incur expenses similar to the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or nonrecurring items.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors, as they eliminate the impact of certain noncash expenses and allow a direct comparison of these measures between periods without the impact of noncash expenses and certain other nonrecurring operating expenses.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) adjusted to exclude interest expense (income), net, income tax expense (benefit), depreciation and amortization, stock-based compensation, acquisition and integration-related costs, goodwill impairment, change in fair value of contingent consideration, severance costs, and other expense (income). Severance costs include severance payments related to the realignment of our resources. Other expense (income) includes foreign exchange gain or loss. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance. We believe Adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry, as this measure generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA have certain limitations, including that they exclude the impact of certain non-cash charges, such as depreciation and amortization, whereas underlying assets may need to be replaced and result in cash capital expenditures, and stock-based compensation expense, which is a recurring charge.

The following table presents, for the periods indicated, a reconciliation of our revenue to Adjusted Gross Profit:

For the three months ended

May 31, 

2023

    

2022

 

(in thousands, except percentages)

 

Revenue

$

93,226

$

85,528

 

Less:

  

  

 

Cost of revenue, excluding depreciation and amortization

(54,203)

(47,615)

 

Gross profit, excluding depreciation and amortization

 

39,023

 

37,913

Add:

 

  

 

  

Stockbased compensation, cost of revenue

 

911

 

1,128

Severance costs, cost of revenue

634

Adjusted Gross Profit

$

40,568

$

39,041

Gross margin, excluding depreciation and amortization

 

41.9

%  

 

44.3

%

Adjusted Gross Margin

 

43.5

%  

 

45.6

%


The following table presents, for the periods indicated, a reconciliation of our Adjusted EBITDA to our net loss:

For the three months ended

May 31, 

2023

    

2022

(in thousands)

Net loss

$

(38,409)

$

(342,822)

Adjusted for:

 

  

 

  

Interest expense (income), net

 

(921)

 

634

Income tax (benefit) expense

 

91

 

(3,899)

Depreciation and amortization

 

11,640

 

11,576

Stockbased compensation

 

14,278

 

19,389

Acquisition and integrationrelated costs(1)

 

27

 

Goodwill impairment

299,705

Severance costs(2)

1,102

Other expense (income)

 

(390)

 

50

Adjusted EBITDA

$

(12,582)

$

(15,367)

(1)For the three months ended May 31, 2023, acquisition and integration-related costs represent expenses associated with litigation inherited through the PlushCare acquisition. Refer to Note 10 in our condensed consolidated financial statements for further details.
(2)Severance costs represent expenses associated with workforce realignment actions taken by management.